Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
290 hedge funds and large institutions have $2.88B invested in Amicus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 108 increasing their positions, 104 reducing their positions, and 42 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 104
2% less call options, than puts
Call options by funds: $4.77M | Put options by funds: $4.87M
5% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 42
1% less funds holding
Funds holding: 293 → 290 (-3)
2.33% less ownership
Funds ownership: 104.53% → 102.2% (-2.3%)
13% less capital invested
Capital invested by funds: $3.31B → $2.88B (-$434M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$47.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$34.8M |
| 4 |
BlackRock
New York
|
+$18.7M |
| 5 |
O
OrbiMed
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$59.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$39.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$30.6M |
| 4 |
Morgan Stanley
New York
|
-$21.8M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$16.2M |
FOLD Hedge Fund Activity: Q4 2024 in Review
290 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2024, worth a combined $2.88B — down 13% from $3.31B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of FOLD and 40 opened new positions — a net loss of 2 holders — while 104 trimmed existing stakes and 108 added.
The largest buyer was Citadel Advisors, adding an estimated $47.9M. The largest seller was JP Morgan Chase, cutting an estimated $59.3M.
- 290 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2024, down from 293 in Q3 2024.
- Funds reported $2.88B of Amicus Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
- 40 funds opened new Amicus Therapeutics positions in Q4 2024 and 42 closed out, a net change of -2 holders.
- The largest Amicus Therapeutics buyer in Q4 2024 was Citadel Advisors, an estimated $47.9M added.
- The largest Amicus Therapeutics seller in Q4 2024 was JP Morgan Chase, an estimated $59.3M sold.
Based on aggregated 13F filings for Q4 2024.